Analysis on the effect of entecavir dispersible tablets on the treatment of patients with decompensated hepatitis B cirrhosis
10.3969/j.issn.1005-1678.2017.08.122
- VernacularTitle:恩替卡韦分散片治疗失代偿期乙肝肝硬化的临床疗效
- Author:
Shengjia LU
;
Changling LIU
;
Tingting SHAO
- Keywords:
entecavir dispersible tablets;
decompensation;
hepatitis B cirrhosis
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(8):289-290
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study and analyze of entecavir dispersible tablets on the treatment of patients with decompensated hepatitis B cirrhosis. Methods From February 2014 to September 2016, 100 patients with decompensated hepatitis B cirrhosis were randomly divided into the control group and the experimental group, 50 patients in each group. The control group were received routine treatment, while the experimental group were received entecavir dispersible tablets treatment on the basis of conventional treatment. The therapeutic effects in the two groups were compared and analyzed. Results The effective rate in the experimental group was 92.0%, and 70.0% in the control group. The effective rate in the experimental group was significantly higher than that in the control group, the difference has statistically significant (P<0.05). The Child-pugh score in the experimental group was (6.12±1.43) points, and the score in the control group was (7.23±1.95) points. The score in the control group was significantly higher than that in the experimental group, with statistical difference (P<0.05). The negative rate of HBeAg in the experimental group was 22.0%, while 86% in the control group the difference has statistically significant (P<0.05). Conclusion The clinical effect is better which entecavir dispersible tablets is used in the treatment of the patients with decompensated hepatitis B cirrhosis, which can improve the treatment efficiency to a great extent, recover the liver function, has the further promotion and application significance.
